Efficacy on the risk of vertebral fracture with administration of once-weekly 17.5 mg risedronate in Japanese patients of established osteoporosis with prevalent vertebral fractures: a 156-week longitudinal observational study in daily practice
- PMID: 27565972
- DOI: 10.1007/s00774-016-0771-x
Efficacy on the risk of vertebral fracture with administration of once-weekly 17.5 mg risedronate in Japanese patients of established osteoporosis with prevalent vertebral fractures: a 156-week longitudinal observational study in daily practice
Abstract
Currently, the only available evidence for the efficacy of once-weekly 17.5 mg risedronate in preventing vertebral fractures was obtained in a 48-week study in Japan. We performed a 156-week prospective, longitudinal, observational study to determine the efficacy of the 17.5 mg risedronate in preventing vertebral fractures. We included Japanese patients with established osteoporosis who were older than 50 years and had radiographically confirmed vertebral fractures. The primary endpoint was the incidence of vertebral fractures every 24 weeks, with the final interval spanning 36 weeks. We also calculated the change in bone mineral density of the lumbar spine (L2-4 BMD) and urinary N-telopeptide of type I collagen (u-NTX), and assessed the incidence of adverse drug reactions and the drug adherence rate. Data from 241 patients were available for analysis of vertebral fracture prevention. The incidence rate of vertebral fractures decreased in a time-dependent manner (P = 0.0006; Poisson regression analysis). The risk ratio (fracture incidence per 100 person-years in the final 36 weeks versus that in the first 24 weeks) was 0.21 (95 % confidence interval 0.08-0.55). Compared to baseline values, L2-4 BMD increased by 6.41 % at 156 weeks, while u-NTX decreased by 36 % at 24 weeks and was maintained thereafter (P < 0.0001). The incidence rate of adverse drug reactions was 9.18 %. Drug adherence rates assessed every 4 weeks were over 90 %. Our results indicate that 156 weeks of treatment with once-weekly 17.5 mg risedronate effectively reduced the risk of vertebral fracture in Japanese patients with established osteoporosis older than 50 years.
Keywords: Established osteoporosis; Lumbar bone mineral density; Observational study; Once-weekly risedronate; Risk of vertebral fracture.
Similar articles
-
Efficacy, tolerability and safety of once-monthly administration of 75mg risedronate in Japanese patients with involutional osteoporosis: a comparison with a 2.5mg once-daily dosage regimen.Bone. 2014 Feb;59:44-52. doi: 10.1016/j.bone.2013.10.017. Epub 2013 Oct 29. Bone. 2014. PMID: 24184313 Clinical Trial.
-
Phase II/III, randomized, double-blind, parallel-group study of monthly delayed-release versus daily immediate-release risedronate tablets in Japanese patients with involutional osteoporosis.J Bone Miner Metab. 2020 Jan;38(1):86-98. doi: 10.1007/s00774-019-01031-x. Epub 2019 Aug 16. J Bone Miner Metab. 2020. PMID: 31420748 Clinical Trial.
-
Efficacy and safety of once-monthly risedronate in osteoporosis subjects with mild-to-moderate chronic kidney disease: a post hoc subgroup analysis of a phase III trial in Japan.J Bone Miner Metab. 2019 Jul;37(4):730-740. doi: 10.1007/s00774-018-0977-1. Epub 2018 Dec 6. J Bone Miner Metab. 2019. PMID: 30523414 Clinical Trial.
-
Update on monthly oral bisphosphonate therapy for the treatment of osteoporosis: focus on ibandronate 150 mg and risedronate 150 mg.Curr Med Res Opin. 2009 Dec;25(12):2951-60. doi: 10.1185/03007990903361307. Curr Med Res Opin. 2009. PMID: 19835464 Review.
-
Consistency of fracture risk reduction in Japanese and Caucasian osteoporosis patients treated with teriparatide: a meta-analysis.J Bone Miner Metab. 2012 May;30(3):321-5. doi: 10.1007/s00774-011-0313-5. Epub 2011 Sep 21. J Bone Miner Metab. 2012. PMID: 21938382
Cited by
-
Bisphosphonates and parathyroid hormone analogs for improving bone quality in spinal fusion: State of evidence.Orthop Rev (Pavia). 2020 Aug 18;12(2):8590. doi: 10.4081/or.2020.8590. eCollection 2020 Aug 6. Orthop Rev (Pavia). 2020. PMID: 32922704 Free PMC article.
-
A 3-year postmarketing study on the safety and effectiveness of once-monthly risedronate in Japanese patients with osteoporosis.Osteoporos Sarcopenia. 2020 Dec;6(4):191-198. doi: 10.1016/j.afos.2020.11.002. Epub 2020 Nov 19. Osteoporos Sarcopenia. 2020. PMID: 33426308 Free PMC article.
-
Anti-fracture Efficacy of Monthly Risedronate Compared with That of Weekly Risedronate in Postmenopausal Korean Women with Osteoporosis: A Nationwide Cohort Study.Korean J Fam Med. 2020 Sep;41(5):339-345. doi: 10.4082/kjfm.19.0110. Epub 2020 May 25. Korean J Fam Med. 2020. PMID: 32447881 Free PMC article.
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical